<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is a condition in which the squamous mucosa that normally lines the distal esophagus is replaced by a columnar type of epithelium </plain></SENT>
<SENT sid="1" pm="."><plain>Although it carries a clear risk of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, the estimation of this risk and therefore the value of endoscopic screening remain highly controversial </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: To investigate more sensitive techniques to identify those patients who are at high risk of developing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and who need intensive endoscopic surveillance for early detection </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A morphologic, histochemical and morphometric study was performed on paraffin-embedded material from 120 patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and 18 with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, each sample was analyzed immunohistochemically with proliferating cell nuclear antigen (PCNA), p53, c-erbB-2, CEA and EMA antibodies </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In <z:hpo ids='HP_0000001'>all</z:hpo> zones of the glandular mucosa we found a higher percentage of PCNA-positive nuclei when the specialized epithelium was present </plain></SENT>
<SENT sid="6" pm="."><plain>We saw PCNA expression in 75% of the patients with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, and p53 expression in 15% of the patients without <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 37% of the patients with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 44% of the patients with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Positivity for c-erbB-2 was found in 38% of the patients without <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 53% of those with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 37% of those with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0004024'>Aneuploidy</z:mp> was found in 70% of the patients with <z:mpath ids='MPATH_160'>metaplasia</z:mpath> or <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and in <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: We conclude that p53, PCNA overexpression and <z:mp ids='MP_0004024'>aneuploidy</z:mp> are markers of risk for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
</text></document>